Alnylam Pharmaceuticals Inc to Present HELIOS-A 18-Month Results - Conference Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst : I guess just in light of the cardiac subgroup data here, can you help us understand a little bit sort of bigger picture, how you're thinking about differences in efficacy in the hereditary versus wild-type cardiomyopathy patients? And I guess maybe even within this like cardiac subgroup looking at some of these endpoints like technetium uptake and echocardiograms, like any learnings in terms of how maybe different genetic subgroups within the cardiac subgroup performed in terms of thinking about potential efficacy in the wild-type cardiac population?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : So across the data sets you showed, patisiran and vutrisiran seem to be pretty similar. So outside of dosing benefit from vutrisiran, is there any other notable benefit for vutrisiran versus patisiran across the different endpoints? Should they be viewed pretty interchangeably from an efficacy standpoint from the data that we've seen thus far? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.